Published in final edited form as:

J Med Chem. 2005 March 10; 48(5): 1330–1335. doi:10.1021/jm049841x.

Solid-Phase Total Synthesis of Kahalalide A and Related Analogues

Line Bourel-Bonnet^{†,§}, Karumanchi V. Rao[‡], Mark T. Hamann[‡], and A. Ganesan^{†,*}

[†]School of Chemistry, University of Southampton, Southampton, SO17 1BJ, United Kingdom

[‡]Department of Pharmacognosy and National Center for Natural Products Research, School of Pharmacy, University of Mississippi, University, Mississippi 38677

Abstract

The marine natural product kahalalide A, a cyclic depsipeptide, was prepared by total synthesis on solid-phase. A backbone cyclization strategy was followed, using the Kenner sulfonamide safety-catch linker. By NMR comparison of synthetic and naturally isolated material, the stereochemistry of the methylbutyrate side chain was established as (*S*). Several analogues were synthesized and tested for antimycobacterial activity. The results indicate that the alcohol functional group in the serine and threonine residues is important, while the methylbutyrate side chain can be replaced by an achiral hexanoate with an increase in activity.

Introduction

Tuberculosis (TB), caused by *Mycobacterium tuberculosis*, is among the most important bacterial diseases.¹ It is estimated that eight million cases of active TB occur every year, predominantly in developing countries, while its prevalence is rising in the Western world particularly among immunocompromised patients (e.g. HIV active). Globally, TB is responsible for two to three million deaths annually. While a number of antimycobacterial medicines are available,² cost and patient compliance are major hurdles for successful treatment. Furthermore, resistance is an increasing problem. Some strains, resistant to as many as nine drugs, result in >50% fatality with current therapies. For these reasons, new antibiotics are desirable, particularly those acting by a novel mechanism of action.

Recently, 48 structurally diverse marine natural product and semisynthetic compounds were screened³ for in vitro activity against *M. tuberculosis*. Within this set, kahalalide A (**1**) emerged as a promising lead, inhibiting 83% of the growth of *M. tuberculosis* at 12.5 µg/mL. Kahalalide A is one of a family of peptide natural products isolated⁴ from the marine mollusk *Elysia rufescens* and its algal diet *Bryopsis* sp. Among these, the tridecapeptide kahalalide F has attracted the most attention⁵ and is currently in phase I clinical trials as an

*Corresponding author. Tel: +44 2380593897; Fax: +44 2380596805; ganesan@soton.ac.uk.

[§]Present address: Faculté de Pharmacie de Lille, UMR 8525 CNRS-Université de Lille 2, 3 rue du Pr Laguesse, BP 83, 59006 Lille CEDEX, France.

Supporting Information Available: HPLC data and ¹H NMR spectra. This material is available free of charge via the Internet at <http://pubs.acs.org>.

anticancer and antipsoriatic agent, while kahalalide B has been the subject⁶ of a total synthesis. Meanwhile, the structurally simpler kahalalide A is one of the few marine-derived cyclic peptides with antimycobacterial activity,⁷ in addition to massetolides,⁸ pitipeptolides,⁹ cyclomarin and sulfactin.¹⁰ Kahalalide A does not have significant homology to these other antimycobacterial cyclic peptides. Furthermore, it is devoid of obviously reactive functional groups, and it is not cytotoxic to various tumor cell lines, suggesting a selective antibacterial target. Here, we report the total synthesis of kahalalide A by a solid-phase route adaptable for analogue preparation. Besides the motivation of discovering biologically active compounds, there was a purely chemical impetus for the total synthesis. The stereochemistry of the methylbutyrate side chain was not established during the original isolation, and we believed this uncertainty could be resolved by synthesis.

kahalalide A (1)

There are two main approaches for the ‘head-to-tail’ solid-phase synthesis¹¹ of cyclic peptides and depsipeptides. In the first, an amino acid is immobilized by its side chain with orthogonal protection at the amine and carboxylic acid. After construction of the linear peptide, ‘head-to-tail’ intramolecular cyclization between the two ends followed by resin cleavage releases the cyclic peptide. In the second strategy, immobilization is through the carboxylic acid, but via a linker that is stable to the conditions of peptide synthesis. After assembly of the linear peptide, the site of immobilization is activated, permitting intramolecular cyclization. The first approach is fundamentally limited to amino acids that have suitable side-chain functionality for immobilization, while the second needs a linker that is robust during linear peptide synthesis and yet selectively activated upon demand. We chose the latter approach, taking advantage of recent developments with Kenner’s sulfonamide ‘safety-catch’ linker. Originally designed¹² for linear peptide synthesis, Kenner’s linker was later popularized¹³ by Ellman for combinatorial chemistry applications. Subsequently, it was demonstrated¹⁴ by Yang and Morriello at Merck that the linker is suitable for the ‘head-to-tail’ synthesis of cyclic peptides, and other groups¹⁵ have recently employed sulfonamide linkers in this manner.

Results and Discussion

The total synthesis of kahalalide A began with the attachment of Fmoc-D-Phe to the commercially available sulfonamide resin, giving **2** (Scheme 1). This step was repeated to ensure high loading, after which peptide couplings (monitored throughout for completion using either 2,4,6-trinitrobenzenesulfonic acid (TNBS)¹⁶ or ninhydrin¹⁷ colorimetric reagents, and also by quantitative Fmoc removal analysis¹⁸) with Fmoc-D-Leu, Fmoc-L-

Thr(*t*-Bu), Fmoc-D-Phe, and amine deprotection provided tetrapeptide **3**. The stage was now set for addition of the methylbutyrate (MeBu) side chain. Unfortunately, only the *S*-enantiomer of chiral 2-methylbutyric acid is commercially available. The synthesis was thus carried out twice, once with the *S*-enantiomer and once with racemic 2-methylbutyrate. The latter would ultimately result in a 50–50 mixture of kahalalide A and its MeBu diastereomer, while the first would produce a single diastereomer (possibly kahalalide A). Deprotection of the Thr side chain in **4** was followed by ester bond formation with Fmoc-L-Ser(*t*-Bu). A double coupling was employed to drive this reaction to completion. Further peptide extension then afforded the key linear heptapeptide **5** for safety-catch activation. According to Yang and Morriello, this is not compatible with the Fmoc group, and the nitrogen protection was first switched to trityl according to their procedure. Sulfonamide alkylation with iodoacetone nitrile then activated the safety-catch linker, and trityl deprotection to the free amine resulted in macrocyclative cleavage of depsipeptide **6** into solution. Acidic cleavage of the *tert*-butyl ethers completed the synthesis of (*S*-MeBu)-kahalalide A and ($\pm$ -MeBu)-kahalalide A. Although the overall yield was modest (15–20%, unoptimized), the crude material produced by the cyclative cleavage strategy¹⁹ was unaccompanied by any significant peptide impurities. In this and later cyclizations, we did not observe the formation of dimers by intermolecular reaction. It is possible that the yields are dependent on which residue is chosen as the initial site of immobilization, although this was not investigated.

HPLC separation of the two diastereomers of ($\pm$ -MeBu)-kahalalide A with a variety of columns proved unsuccessful. Nevertheless, careful examination of ¹H NMR spectra allowed assignment of the MeBu stereochemistry. The ¹H NMR spectra of naturally isolated kahalalide A and synthetic (*S*-MeBu)-kahalalide A (Figure 1a and 1b, respectively) in CD₃CN are closely identical. These spectra differed significantly from the spectra of ($\pm$ -MeBu)-kahalalide A (Figure 1c).

For comparison, ¹H NMR spectra of a mixture of natural kahalalide A and ($\pm$ -MeBu)-kahalalide A (Figure 2a), and a mixture of synthetic (*S*-MeBu)-kahalalide A and ($\pm$ -MeBu)-kahalalide A (Figure 2b) were also recorded. The 2-CH, 3-CH₂, 4-CH₃, and 5-CH₃ protons of the 2-methylbutyric acid moiety showed similar NMR patterns, but there were significant differences between the chemical shift sets for these signals in the two molecules. From these observations, it was possible to establish unambiguously the differences between (*S*-MeBu)-kahalalide A and ($\pm$ -MeBu)-kahalalide A. For ($\pm$ -MeBu)-kahalalide A, the 2-methyl group protons of 2-methylbutyric acid appeared as a multiplet at lower chemical shift than the corresponding signal for the *S*-isomer. On the other hand, the 2-methyl group protons of 2-methylbutyric acid for (*S*-MeBu)-kahalalide A appeared as a doublet and exactly matched with those for natural kahalalide A. From this study, it could be determined that the 2-methylbutyric acid of kahalalide A has the *S*-configuration. Our choice of *S*-methylbutyric acid for the synthesis, dictated by practical grounds, fortuitously turned out to provide the right diastereomer.

With the total synthesis successfully accomplished, we prepared two analogues aimed at probing the importance of the methylbutyrate side chain. In the first, the arm containing (MeBu)-Phe was deleted and replaced by a simple acetyl group. In the second, the methylbutyrate was replaced by the longer achiral hexanoate. In all these syntheses,

depsipeptides with protected Ser and Thr residues are first produced by cyclative cleavage from the resin, and they were tested alongside with the deprotected material.

The full set of compounds (**7–14**, Figure 3) was tested for antimycobacterial activity. The results reveal a number of structure–activity relationships. First, all compounds containing protected Ser and Thr *tert*-butyl ethers were inactive, indicating the importance of the free alcohol at these positions. The truncated (Ac)-kahalalide **12**, in which a Phe residue and the methylbutyrate side chain are removed, was also inactive. Meanwhile, (*S*-MeBu)-kahalalide A and ($\pm$ -MeBu)-kahalalide A were equally potent, implying that the stereochemistry of the methylbutyrate is not important for antimycobacterial activity. Indeed, replacement by the achiral hexanoate (**14**) resulted in a 2-fold increase in potency over the natural product.

The increased conformational constraints placed by converting a linear peptide into a cyclic skeleton usually have a marked effect on its properties and biological activity. To test this in the present context, a smallscale methanolysis was carried out with synthetic kahalalide A to cleave the depsipeptide linkage (Scheme 2). The resulting ‘linear’ kahalalide A proved to be devoid of antimycobacterial activity, and this avenue was not pursued further.

To summarize, an efficient solid-phase total synthesis of kahalalide A was achieved. To the best of our knowledge, this is the first example where the Kenner safety-catch linker was used for the preparation of cyclic depsipeptides. By careful NMR analysis of synthetic kahalalide A containing either (*S*-MeBu) or ($\pm$ -MeBu), we have established that the natural product contains a (*S*)-2-methylbutyrate subunit, thus resolving the only ambiguity in its structure. Our route is readily amenable to the preparation of libraries for antimycobacterial testing, by amino acid substitutions during the synthesis. The data from our first analogues highlight the importance of the free Ser and Thr side chains and the constrained depsipeptide framework for biological activity. The methylbutyrate side chain can be replaced by other hydrophobic groups, as evidenced by increased activity with the hexanoate. On the basis of these preliminary results, we plan the synthesis of additional analogues and mechanistic studies to identify the target of action.

Experimental Methods

Materials

All Fmoc amino acids, coupling reagents, and resin were purchased from Novabiochem, and other chemicals are from Aldrich. Dichloromethane and triethylamine were distilled over CaH₂ and THF distilled over Na in the presence of benzophenone. The inside surfaces of peptide synthesis reactors were pretreated by dichlorodimethylsilane, then rinsed with methanol and dichloromethane.

General Procedure for Depsipeptide Synthesis

Resin loading: To the 4-sulfamylbutyryl AM resin (Novabiochem, 500 mg, 0.56 mmol) preswollen in DMF was added Fmoc-D-Phe-OH (697 mg, 1.8 mmol), PyBOP (936 mg, 1.8 mmol) and Hünig's base (942.8 μ L, 5.4 mmol) in 5 mL of DMF. The reaction mixture was left overnight, and the coupling repeated twice more. The efficiency of loading was determined by Fmoc removal analysis.

Peptide coupling: The Fmoc-peptidyl resin, swollen in DMF, was deprotected by 20% piperidine in DMF for 2 min, and the deprotection repeated for 20 min. The resin is washed (3 × DMF) and the presence of the amino group checked with TNBS. At the same time, the next Fmoc amino acid (2.24 mmol) is activated in 5 mL of DMF by DIC (2.24 mmol, 351 μL) and HOBt (2.24 mmol, 351 mg). The solution is filtrated in case of precipitation, before addition to the deprotected peptidyl resin. Reaction completion is checked by TNBS or ninhydrin. The coupling of acetic, 2-methylbutyric, or hexanoic acids was carried out under identical conditions.

Depsipeptide bond formation: The threonine *tert*-butyl ether is deprotected by a TFA/TIS/water (95/2.5/2.5) mixture for 2 min. The procedure was repeated for 30 min and the resin washed (CH₂Cl₂, THF). The alcohol resin was incubated with DMAP (27.3 mg, 0.224 mmol) and reacted in 4 mL of THF with Fmoc-L-Ser(*t*-Bu)-OH (859 mg, 2.24 mmol) and DIC (351 mg, 2.24 mmol). This coupling was first done for 2 h and repeated overnight to ensure complete esterification as quantified by Fmoc removal analysis. After resin washing (3 × THF, 3 × DMF), elongation of the linear peptide is continued, until the Fmoc group on the last residue is removed.

Safety-catch activation and cyclative cleavage of cyclic depsipeptides: The amine resin is treated with trityl chloride (624 mg, 2.24 mmol) and Hünig's base (782 μL, 4.48 mmol) in 2.5 mL of CH₂Cl₂ for 2 h or left overnight. After CH₂Cl₂ washings and TNBS test, the sulfonamide linker is activated by iodoacetonitrile (405 μL, 5.6 mmol) and Hünig's base (1.73 mL, 6.72 mmol) in 2.5 mL of *N*-methylpyrrolidinone for 12 h. This activation step was repeated under the same conditions. After resin washing (*N*-methylpyrrolidinone, CH₂Cl₂), the trityl group is removed by 5% TFA in CH₂Cl₂ treatment for 2 min. The deprotection was repeated for 2 h, followed by a TNBS test. The linear peptidyl resin is then washed (3 × CH₂Cl₂, 3 × THF, once by 1% Hünig's base in THF). Immediately afterward, the resin is swollen in THF and Hünig's base (293 μL, 1.68 mmol) added. The cyclization proceeds overnight, releasing the cyclic depsipeptide.

Peptide purification: The supernatant from cyclative cleavage is concentrated to the crude cyclic peptide, whose identity is checked by ES-MS and purity by HPLC and TLC. The compound is then purified by column chromatography (silica) to give peptides with protected Ser/Thr residues. Side-chain deprotection is performed by TFA/*i*-Pr₃SiH/water (95/2.5/2.5) for 30 min, followed by precipitation of the peptide in Et₂O dried over CaH₂. Deprotected peptides are further purified by preparative RP-HPLC (C-18 Nucleosil 300 mm × 25 mm, 3 mL/min, detection at 230 nm, eluent A: Water/TFA: 99.95/0.05, eluent B: acetonitrile/water/TFA 80/19.95/0.05, gradient B from 0 to 100% in 100 min).

(*R/S*)-Methyl-2-butyryl-D-Phe-cyclo[L-Thr-D-Leu-D-Phe-D-Leu-L-Thr(*t*-Bu)-L-Ser(*t*-Bu)] (7)—Overall yield: 19% (104 mg). ES-MS: 1028.5 [M + Na]⁺; HPLC purity: 98% by ELSD, 90% at 220 nm; TLC (CH₂Cl₂/AcOEt/TEA: 6/4/0.05) *R*_f: 0.3.

(*R/S*)-Methyl-2-butyryl-D-Phe-cyclo[L-Thr-D-Leu-D-Phe-D-Leu-L-Thr-L-Ser](*±*-MeBu)-kahalalide A, 8—Deprotection yield: 95%, overall yield: 18% (17 mg). ES-MS: 916.7 [M + Na]⁺; HPLC purity: >99% by ELSD, 87% at 220 nm.

(S)-Methyl-2-butyryl-D-Phe-cyclo[L-Thr-D-Leu-D-Phe-D-Leu-L-Thr(*t*-Bu)-L-Ser(*t*-Bu)] (9)—Overall yield: 15% (85 mg). ES-MS: 1029.0 [M + Na]⁺; HPLC purity: 98% by ELSD, >99% at 220 nm; TLC (CH₂Cl₂/AcOEt/NH₄OH aq: 7/3/0.05) *R*_F: 0.3.

(S)-Methyl-2-butyryl-D-Phe-cyclo[L-Thr-D-Leu-D-Phe-D-Leu-L-Thr-L-Ser] (kahalalide A, 10)—*tert*-Butyl ether deprotection yield: 75%, overall yield: 11% (12 mg). ¹H NMR δ 8.21 (Thr2-NH, d, *J* 9.59 Hz), 7.63 (Phe1-NH, d, *J* 9.45 Hz), 7.63 (Thr1-NH, d, *J* 9.45 Hz), 7.45 (Leu2-NH, d, *J* 9.37 Hz), 7.37 (Phe2-NH, d, *J* 4.68 Hz), 7.25 (Phe2-H_{5,5',6,6',7}, Phe1-H_{5,5',6,6',7}, m), 7.23 (Leu1-NH, m), 6.87 (Ser-NH, d, *J* 5.70 Hz), 5.44 (Thr2-H₃, dq, *J* 6.16, 2.18 Hz), 5.04 (Phe2-H₂, dt, *J* 7.98, 4.90 Hz), 4.77 (Phe1-H₂, m), 4.70 (Leu1-H₂, m), 4.48 (Thr1-H₃, dq, *J* 6.49, 1.89 Hz), 4.40 (Thr2-H₂, dd, *J* 9.56, 2.16 Hz), 4.29 (Leu2-H₂, q, *J* 9.27 Hz), 4.02 (Thr1-H₂, m), 4.02 (Ser-H₂, m), 3.52 (Ser-H₃, dd, *J* 5.16, 1.63 Hz), 3.24 (Phe1-H₃, dd, *J* 14.18, 5.13 Hz), 3.00 (Phe2-H₃, dd, *J* 14.18, 5.13 Hz), 2.80 (Phe1-H_{3'}, dd, *J* 14.27, 10.4 Hz), 2.4 (MeBu-H₂, m), 1.65 (Leu1-H₄, m), 1.55 (MeBu-H₃, m), 1.50 (Leu1-H₃, m), 1.29 (Thr1-H₄, d, *J* 6.51 Hz), 1.20 (Leu2-H₃, t, *J* 7.63 Hz), 1.13 (MeBu-H₅, d, *J* 6.90 Hz), 1.02 (Leu2-H₄, m), 0.91 (Leu1-H₅, d, *J* 6.42 Hz), 0.90 (MeBu-H₄, t, *J* 7.40 Hz), 0.89 (Leu1-H₆, d, *J* 6.42 Hz), 0.74 (Leu2-H₅, d, *J* 6.53 Hz), 0.68 (Leu2-H₆, d, *J* 6.53 Hz), 0.61 (Thr2-H₄, d, *J* 6.58 Hz); ¹³C NMR δ 180.6 (MeBu-C₁), 175.3 (Leu1-C₁), 174.3 (Phe2-C₁), 172.1 (Leu2-C₁), 171.9 (Phe1-C₁), 170.9 (Thr1-C₁), 170.0 (Ser-C₁), 169.3 (Thr2-C₁), 138.0 (Phe1-C₄), 137.4 (Phe2-C₄), 130.2 (Phe2-C_{5,5'}), 129.7 (Phe1-C_{5,5'}), 129.3 (Phe2-C_{6,6'}), 129.3 (Phe1-C_{6,6'}), 127.8 (Phe2-C₇), 127.6 (Phe1-C₇), 69.9 (Thr2-C₃), 66.4 (Thr1-C₃), 61.7 (Ser-C₃), 60.8 (Thr1-C₂), 57.2 (Ser-C₂), 56.86 (Phe2-C₂), 56.86 (Thr2-C₂), 55.5 (Phe1-C₂), 54.2 (Leu2-C₂), 52.4 (Leu1-C₂), 43.4 (Leu1-C₃), 42.9 (MeBu-C₂), 42.3 (Leu2-C₃), 39.8 (Phe1-C₃), 37.7 (Phe2-C₃), 28.3 (MeBu-C₃), 25.5 (Leu2-C₄), 25.2 (Leu1-C₄), 23.0 (Leu2-C₆), 22.8 (Leu1-C₆), 22.6 (Leu1-C₅), 21.9 (Leu2-C₅), 20.8 (Thr1-C₄), 17.9 (MeBu-C₅), 16.0 (Thr2, C₄), 12.3 (MeBu-C₄); ES-MS: 916.17 [M + Na]⁺; HPLC purity: 97% by ELSD, >99% at 220 nm.

Ac-cyclo[L-Thr-D-Leu-D-Phe-D-Leu-L-Thr(*t*-Bu)-L-Ser(*t*-Bu)] (11)—Overall yield: 5% (26 mg). ES-MS: 855 [M + K]⁺; HPLC purity: >99% by ELSD, 68% at 220 nm; TLC (CH₂Cl₂/AcOEt/TEA: 5/5/0.05) *R*_F: 0.3.

Ac-cyclo[L-Thr-D-Leu-D-Phe-D-Leu-L-Thr-L-Ser] (12)—Deprotection yield: 59%, overall yield: 3% (7 mg). ¹H NMR δ 9.08 (Thr1-NH, d, *J* 7.57 Hz), 8.12 (Phe1-NH, m), 8.05 (Leu1-NH, d, *J* 6.94 Hz), 7.90 (Ser-NH, m), 7.78 (Thr2-NH, d, *J* 9.18 Hz), 7.33 (Leu2-NH, m), 7.25 (Phe-H_{5,5',6,6',7}, m), 5.28 (Thr2-H₃, d, *J* 5.76 Hz), 4.63 (Thr2-H₂, d, *J* 8.93 Hz), 4.59 (Leu1-H₂, d, *J* 6.95 Hz), 4.29 (Phe-H₂, m), 4.27 (Thr1-H₃, dd, *J* 6.62, 2.45 Hz), 4.16 (Leu2-H₂, m), 4.02 (Thr1-H₂, m), 3.53 (Ser-H_{2,3}, m), 3.17 (Phe-H_{3'}, dd, *J* 13.92, 5.00 Hz), 3.00 (Phe-H₃, dd, *J* 13.83, 10.39 Hz), 1.56 (Leu1-H₃, Leu2-H₃, m), 1.35 (Leu2-H₄, m), 1.09 (Thr1-H₄, d, *J* 6.44 Hz), 1.04 (Thr2-H₄, d, *J* 6.72 Hz), 0.91 (Leu1-H₅, d, *J* 6.42 Hz), 0.90 (Leu1-H₄, m), 0.79 (Leu1-H_{6'}, d, *J* 6.02 Hz), 0.74 (Leu1-H₆, d, *J* 5.94 Hz), 0.55 (Leu2-H_{5'}, d, *J* 6.54 Hz), 0.42 (Leu2-H₅, d, *J* 6.55 Hz); ¹³C NMR δ 174.0, 172.4, 171.5, 171.2, 170.8, 170.6, 170.1 (all C₁), 138.0, 130.2, 129.8, 129.1, 128.9, 127.2 (Phe1-C₄, C_{5,5'}, C_{6,6'} and C₇), 71.3 (Thr2-C₃), 66.4 (Thr1-C₃), 61.3 (Ser-C₂), 61.2 (Ser-C₃), 60.4 (Thr1-C₂), 56.5 (Phe1-C₂), 56.4 (Leu2-C₂), 55.4 (Thr2-C₂), 52.2 (Leu1-C₂), 42.9 (MeBu-

C₂), 40.6 (Leu1-C₃), 40.4 (Leu2-C₃), 37.3 (Phe1-C₃), 25.1, 24.8, 23.8; 23.5, 23.4, 23.3, 23.1, 22.9, 22.7, 22.1.4, 21.1 (Leu2-C₄, Leu1-C₄, Leu2-C₆, Leu1-C₆, Leu1-C₅, Leu2-C₅, Thr1-C₄, Thr2-C₄, Ac-C₂); ES-MS: 727.7 [M + Na]⁺; HPLC purity: 96% by ELSD, 77% at 220 nm.

Hexanoyl-D-Phe-cyclo[L-Thr-D-Leu-D-Phe-D-Leu-L-Thr(*t*-Bu)-L-Ser(*t*-Bu)] (13)—

Overall yield: 15% (88 mg). ES-MS: 1043.0 [M + Na]⁺; HPLC purity: 98% by ELSD, 74% at 220 nm; TLC (CH₂Cl₂/AcOEt/TEA: 7/3/0.05) *R*_f: 0.3.

Hexanoyl-D-Phe-cyclo[L-Thr-D-Leu-D-Phe-D-Leu-L-Thr-L-Ser] (14)—Deprotection

yield: 93%, overall yield: 14% (14 mg). ¹H NMR δ 8.20 (Thr2-NH, d, *J* 9.49 Hz), 7.78 (Phe1-NH, d, *J* 9.73 Hz), 7.62 (Thr1-NH, d, *J* 7.21 Hz), 7.54 (Leu2-NH, d, *J* 9.46 Hz), 7.45 (Phe2-NH, d, *J* 4.44 Hz), 7.27 (Phe2-H_{5,5',6,6',7} Phe1-H_{5,5',6,6',7}, m), 7.25 (Leu1-NH, m), 6.86 (Ser-NH, d, *J* 6.02 Hz), 5.47 (Thr2-H₃, dq, *J* 6.50, 2.20 Hz), 5.03 (Phe2-H₂, dt, *J* 8.18, 4.56 Hz), 4.81 (Leu1-H₂, m), 4.73 (Phe1-H₂, m), 4.51 (Thr1-H₃, dq, *J* 6.53, 1.92 Hz), 4.40 (Thr2-H₂, dd, *J* 9.57, 2.17 Hz), 4.31 (Leu2-H₂, q, *J* 9.4 Hz), 4.02 (Thr1-H₂, m), 3.99 (Ser-H₂, dd, *J* 6.93, 1.63 Hz), 3.54 (Ser-H₃, d, *J* 4.89 Hz), 3.23 (Phe1-H₃, dd, *J* 14.04, 4.91 Hz), 3.02 (Phe2-H₃, dd, *J* 7.85, 1.79 Hz), 2.86 (Phe1-H₄, dd, *J* 14.10, 10.25 Hz), 2.3 (Hex-H₂, t, *J* 7.5 Hz), 1.66 (Hex-H₃, m), 1.59 (Leu1-H₄, m), 1.50 (Leu1-H₃, m), 1.37 (Hex-H_{4,5}, m), 1.32 (Thr1-H₄, d, *J* 6.48 Hz), 1.22 (Leu2-H₃, m), 1.06 (Leu2-H₄, m), 0.96 (Leu1-H₅, d, *J* 6.37 Hz), 0.92 (Hex-H₆, t, *J* 7.1 Hz), 0.92 (Leu1-H₆, d, *J* 6.49 Hz), 0.79 (Leu2-H₅, d, *J* 6.53 Hz), 0.73 (Leu2-H₆, d, *J* 6.51 Hz), 0.61 (Thr2-H₄, d, *J* 6.56 Hz); ¹³C NMR δ 177.0 (Hex-C₁), 174.8 (Leu1-C₁), 173.6 (Phe2-C₁), 171.6 (Leu2-C₁), 171.4 (Phe1-C₁), 170.4 (Thr1-C₁), 169.6 (Ser-C₁), 168.7 (Thr2, C₁), 137.6 (Phe1-C₄), 136.8 (Phe2-C₁), 129.8 (Phe2-C_{5,5'}), 129.4 (Phe1-C_{5,5'}), 128.9 (Phe2-C_{6,6'}), 128.9 (Phe1-C_{6,6'}), 127.4 (Phe2-C₇), 127.2 (Phe1-C₇), 69.5 (Thr2-C₃), 65.9 (Thr1-C₃), 61.3 (Ser-C₃), 60.5 (Ser-C₂), 56.7 (Thr1-C₂), 56.6 (Phe2-C₂), 56.3 (Thr2-C₂), 55.2 (Phe1-C₂), 53.8 (Leu2-C₂), 51.9 (Leu1-C₂), 42.6 (Leu1-C₃), 42.0 (Leu2-C₃), 39.2 (Phe1-C₃), 37.1 (Phe2-C₃), 36.2 (Hex-C₂), 31.4 (Hex-C₄), 26.5 (Hex-C₃), 25.0 (Leu1-C₄), 24.8 (Leu2-C₄), 22.8 (Leu1-C₆), 22.52 (Hex-C₅), 22.51 (Leu2-C₆), 22.3 (Leu1-C₅), 21.6 (Leu2-C₅), 20.2 (Thr1-C₄), 17.6 (Thr2-C₄), 15.5 (Hex-C₆); ES-MS: 930.6 [M + Na]⁺, 946.7 [M + K]⁺; HPLC purity: 96% by ELSD, 77% at 220 nm.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

L.B. and A.G. acknowledge the Faculty of Pharmacy, University of Lille 2, for financial support. We are grateful to Mrs. Joan Street and Dr. John Langley at Southampton for NMR and MS support, respectively; the late Professor Paul J. Scheuer at the University of Hawaii for a sample of naturally isolated kahalalide A; Professor Christian Roussel at the University of Marseille and Professor Daniel Armstrong and Dr. Alain Berthod at Iowa State University for attempted separation of (±-MeBu)-kahalalide A; and Dr. Fangqiu Zhang and Professor Scott Franzblau at the College of Pharmacy, University of Illinois at Chicago, for antimycobacterial testing. K.V.R. and M.T.H. acknowledge the NIH for financial support and thank Frank Wiggers and Chuck Dunbar from the National Center for Natural Products Research for assistance in recording NMR spectra.

References

1. (a) Davies PDO. The worldwide increase in tuberculosis: how demographic changes, HIV infection and increasing numbers in poverty are increasing tuberculosis. *Ann. Med.* 2003; 35:235–243. [PubMed: 12846265] (b) Shingadia D, Novelli V. Diagnosis and treatment of tuberculosis in children. *Lancet Infect. Dis.* 2003; 3:624–632. [PubMed: 14522261] (c) Glynn JR. Resurgence of tuberculosis and the impact of HIV infection. *Br. Med. Bull.* 1998; 54:579–593. [PubMed: 10326286]
2. Chan ED, Iseman MD. Current medical treatment for tuberculosis. *Br. J. Med.* 2002; 325:1282–1286.
3. El Sayed KA, Bartyzel P, Shen X, Perry TL, Zjawiony JK, Hamann MT. Marine natural products as antituberculosis agents. *Tetrahedron.* 2000; 56:949–953.
4. (a) Hamann MT, Otto CS, Scheuer PJ, Dunbar DC. Kahalalides: Bioactive peptides from a marine mollusk *Elysia rufescens* and its algal diet *Bryopsis* sp. *J. Org. Chem.* 1996; 61:6594–6600. [PubMed: 11667527] (b) Goetz G, Nakao T, Scheuer PJ. Two acyclic kahalalides from the sacoglossan mollusk *Elysia rufescens*. *J. Nat. Prod.* 1997; 60:562–567. (c) Kan Y, Fujita T, Sakamoto B, Hokama Y, Nagai H, Kahalalide K. A new cyclic depsipeptide from the Hawaiian green alga *Bryopsis* species. *J. Nat. Prod.* 1999; 62:1169–1172. [PubMed: 10479330] (d) Horgen FD, de los Santos DB, Goetz G, Sakamoto B, Kan Y, Nagai H, Scheuer PJ. A new depsipeptide from the sacoglossan mollusk *Elysia ornata* and the green alga *Bryopsis* species. *J. Nat. Prod.* 2000; 63:152–154. [PubMed: 10650101]
5. (a) Becerro MA, Goetz G, Paul VJ, Scheuer PJ. Chemical defenses of the sacoglossan mollusk *Elysia rufescens* and its host alga *Bryopsis* sp. *J. Chem. Ecol.* 1999; 27:2287–2299. [PubMed: 11817082] (b) Lopez-Macià A, Jiménez JC, Royo M, Giralt E, Albericio F. Synthesis and structure determination of kahalalide F. *J. Am. Chem. Soc.* 2001; 123:11398–11401. [PubMed: 11707116] (c) Bonnard I, Manzanares I, Rinehart KL. Stereochemistry of kahalalide F. *J. Nat. Prod.* 2003; 66:1466–1470. [PubMed: 14640520]
6. Lopez-Macià A, Jiménez JC, Royo M, Giralt E, Albericio F, Kahalalide B. Synthesis of a natural cyclodepsipeptide. *Tetrahedron Lett.* 2001; 41:9765–9769.
7. Copp BR. Antimycobacterial natural products. *Nat. Prod. Rep.* 2003; 6:535–557. [PubMed: 14700198]
8. Gerard J, Lloyd R, Barsby T, Haden P, Kelly MT, Andersen RJ, Massetolides A–H. Antimycobacterial cyclic depsipeptides produced by two *Pseudomonads* isolated from marine habitats. *J. Nat. Prod.* 1997; 60:223–229. [PubMed: 9157190]
9. Luesch H, Pangilinan R, Yoshida WY, Moore RE, Paul VJ. Pitipeptolides A and B, new cyclodepsipeptides from the marine cyanobacterium *Lyngbya majuscula*. *J. Nat. Prod.* 2001; 64:304–307. [PubMed: 11277744]
10. Waters B, Saxena G, Wanggui Y, Kau D, Wrigley S, Stokes R, Davies J. Identifying protein kinase inhibitors using an assay based on inhibition of aerial hyphae formation in *Streptomyces*. *J. Antibiot.* 2002; 55:407–416. [PubMed: 12061549]
11. (a) Lambert JN, Mitchell JP, Roberts KD. The synthesis of cyclic peptides. *J. Chem. Soc., Perkin Trans.* 2001; 1:471–484. (b) Ballard CE, Yu H, Wang B. Recent developments in depsipeptide research. *Curr. Med. Chem.* 2002; 9:471–498. [PubMed: 11945121] (c) Li P, Roller PP, Xu JC. Current synthetic approaches to peptide and peptidomimetic cyclization. *Curr. Org. Chem.* 2002; 6:411–440. (d) Davies JS. The cyclization of peptides and depsipeptides. *J. Peptide. Sci.* 2003; 9:471–501. [PubMed: 12952390]
12. Kenner GW, McDermott JR, Sheppard RC. Safety catch principle in solid-phase peptide synthesis. *J. Chem. Soc., Chem. Commun.* 1971:636–637.
13. (a) Backes BJ, Ellman JA. Carbon–carbon bond-forming methods on solid support. Utilization of Kenner's "safety-catch" linker. *J. Am. Chem. Soc.* 1994; 116:11171–11172. (b) Backes BJ, Virgilio AA, Ellman JA. Activation method to prepare a highly reactive acylsulfonamide "safety-catch" linker for solidphase synthesis. *J. Am. Chem. Soc.* 1996; 118:3055–3056.
14. Yang L, Morriello G. Solid-phase synthesis of "head-to-tail" cyclic peptides using a sulfonamide "safety-catch" linker: the cleavage by cyclization approach. *Tetrahedron Lett.* 1999; 40:8197–8200.

15. (a) de Visser PC, Kriek NMAJ, van Hooft PAV, Van Schepdael A, Filippov DV, van der Marel GA, Overkleeft HS, van Boom JH, Noort D. Solid-phase synthesis of polymyxin B-1 and analogues via a safety-catch approach. *J. Pept. Res.* 2003; 61:298–306. [PubMed: 12753377] (b) Qin C, Bu X, Wu X, Guo Z. A chemical approach to generate molecular diversity based on the scaffold of cyclic decapeptide antibiotic tyrocidine A. *J. Comb. Chem.* 2003; 5:353–355. [PubMed: 12857101] (c) Qin C, Zhong X, Bu X, Ng NLJ, Guo Z. Dissociation of antibacterial and hemolytic activities of an amphipathic peptide antibiotic. *J. Med. Chem.* 2003; 46:4830–4833. [PubMed: 14584933]
16. Hancock WS, Battersby JE. A new micro-test for the detection of incomplete coupling reactions in solid-phase peptide synthesis using 2,4,6-trinitrobenzenesulfonic acid. *Anal. Biochem.* 1976; 74:260–264. [PubMed: 962081]
17. Kaiser E, Colescott RL, Bossinger CD, Cook PI. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. *Anal. Biochem.* 1970; 34:595–598. [PubMed: 5443684]
18. Chan, WC.; White, PD. Fmoc solid-phase synthesis. Chan, WC.; White, PD., editors. Oxford: Oxford University Press; 2000. p. 63
19. Ganesan, A. Cyclative cleavage strategies for the solid-phase synthesis of heterocycles and natural products. In: Bunin, BA.; Morales, GA., editors. *Methods in Enzymology; Combinatorial Chemistry, Part B*. Vol. 369. San Diego: Academic Press; 2003. p. 415-434.

Figure 1.
 ^1H NMR spectrum in CD_3CN , showing the methyl region of (a) naturally isolated kahalalide A, (b) (*S*-MeBu)-kahalalide A and (c) ($\pm$ -MeBu)-kahalalide A.

Figure 2.
¹H NMR spectrum of methyl region of a mixture of (a) naturally isolated kahalalide A and (±-MeBu)-kahalalide A, and (b) (*S*-MeBu)-kahalalide A and (±-MeBu)-kahalalide A.

(±-MeBu)-kahalalide A
protected, **7** R = *t*-Bu, inactive
unprotected, **8**, R = H, MIC 64 µg/mL

(9S)-kahalalide A
protected, **9**, R = *t*-Bu, inactive
unprotected, **10**, R = H, MIC 64 µg/mL

(Ac)-kahalalide A
protected, **11** R = *t*-Bu, inactive
unprotected, **12**, R = H, inactive

(Hex)-kahalalide A
protected, **13**, R = *t*-Bu, inactive
unprotected, **14**, R = H, MIC 32 µg/mL

Figure 3.
Compounds prepared, with antimycobacterial activity indicated.

Scheme 1^a

^a Reagents: (a) (i) 20% piperidine/DMF; (ii) Fmoc-D-Leu-OH, DIC, HOBt (4 equiv each); (iii) 20% piperidine/DMF; (iv) Fmoc-L-Thr(*t*-Bu)-OH, DIC, HOBt (4 equiv each); (v) 20% piperidine/DMF; (vi) Fmoc-D-Phe-OH, DIC, HOBt (4 equiv each); (vii) 20% piperidine/DMF; (b) (*S*)-2-methylbutyric acid or ($\pm$)-2-methylbutyric acid, DIC, HOBt (4 equiv each); (c) (i) TFA/*i*-Pr₃SiH/H₂O: 95:2.5:2.5; (ii) Fmoc-L-Ser(*t*-Bu)-OH, DIC, (4 equiv each), 0.4 equiv of DMAP; (iii) 20% piperidine/DMF; (iv) Fmoc-L-Thr(*t*-Bu)-OH, DIC, HOBt (4 equiv each); (v) 20% piperidine/DMF; (vi) Fmoc-D-Leu-OH, DIC, HOBt (4 equiv each); (d) (i) 20% piperidine/DMF; (ii) 4 equiv of Trt-Cl, 8 equiv *i*-Pr₂NEt; (iii) 10 equiv of ICH₂CN, 12 equiv of *i*-Pr₂NEt; (iv) 5% TFA/CH₂Cl₂; 3 equiv of *i*-Pr₂NEt; (e) TFA/*i*-Pr₃SiH/H₂O.

Scheme 2.